This person is a member of Sanger Institute Alumni.
I left the Sanger Institute 27/01/2023 after being employed for 9 months and, during this time, I had the pleasure of working with an amazing team while gaining invaluable experience and developing a wide range of useful skills.
Interested in research into precision medicines and combination therapies to target treatment-resistant cancers. As a Research Assistant within the Garnett Group Screening Team, primarily performed pooled CRISPR screens and high-throughput drug screens to identify novel synthetic lethalities or potential drug combinations in cancer utilising a range of cell line and organoid models.
Project ENCORE & Project SCORE 3D
These projects involved performing numerous pooled CRISPR screens to identify genes essential to cancer cell growth (known as synthetic lethalities). These genes are then used as starting points for research into potential novel therapies.
This project involved drugging various cancer cell line models with a range of different compounds to identify potentially effective treatments as well as combinations to overcome resistance.